Wednesday, November 30, 2016 6:47:01 AM
Use of CytoSorb in severe sepsis after hemicolectomy and anastomosis dehiscence
Dr. Milan Margoc, Dr. S. Montag, Doz. Alexander Kulier, Anaesthesiological Intensive Care Unit, Hospital-Elisabethinen Linz
This case study reports on a 80-year-old female patient (previous medical history of: arterial hypertension, coronary heart disease, atrial fibrillation, NIDDM II, aortic stenosis, peripheral vascular disease, chronic renal failure III), who was admitted to hospital for elective right-sided hemicolectomy for colon carcinoma.
Case presentation
Admission to normal surgical ward for scheduled operation and subsequent postoperative transfer to intensive care unit
Her stay on ICU was complicated by secondary bleeding on the 1st postoperative day necessitating an immediate re-laparotomy with removal of hematoma
After a short stay in ICU, transfer to the normal surgical ward for further treatment for a total of 10 days
On the 10th day, acute deterioration of her general condition, diagnosis of severe sepsis after anastomosis dehiscence with fecal peritonitis
Immediate surgical care with re-laparotomy, anastomotic resection, installation of a new anastomosis, lavage and drainage
Antibiotic therapy initially with tazobactam/piperacillin and after microbiological findings were available, changed to meropenem/echocantine (gram-negative sepsis)
8 days later again deterioration with re-laparotomy and placement of a terminal ileostoma and abdominal dressing (VAC treatment for wound closure)
Retransfer to ICU, orotracheally intubated, mechanically ventilated, noradrenaline-dependent with doses of
0.5-0.83 µg/kg/min at a heart rate of 90-140/min and a blood pressure of 80/45 mmHg, which improved to
110/60 mmHg with noradrenaline
At this point she exhibited highly elevated inflammatory parameters (CRP 33.7 mg/l, leukocytes 28.400/µl,
PCT 75 ng ml)
Additional impairment of renal function: GFR 14.7 ml/min
Due to her acute-on-chronic renal insufficiency as well as her hemodynamic instability and the increased inflammatory markers, the decision was made to initiate CytoSorb as an adjunctive therapy together with CVVHD
Treatment
Two treatments with CytoSorb for a total treatment time of 66 hours (1st and 2nd treatment for 24 hours each, treatment pause of 18 hours between both treatments)
CytoSorb was used in conjunction with CRRT (Multifiltrate, Fresenius Medical Care) performed in CVVHD mode
Blood flow rate: 150 ml/min
Anticoagulation: citrate
CytoSorb adsorber position: pre-hemofilter
Measurements
Demand for catecholamines
Renal function (GFR, excretion)
Inflammatory parameters (CRP, PCT, leucocytes)
Results
Hemodynamic stabilization with a significant reduction in catecholamine doses –norepinephrine doses could be reduced to 0.09-0.2 µg/kg/min during both treatments, patient was free from catecholamines 96 hours after completion of both CytoSorb treatments
Clear reduction of inflammatory parameters under CytoSorb therapy (CRP 10.38 mg/l, leucocytes 14.500/µl, PCT 22.5 ng/ml)
Clear improvement in kidney function: GFR from 14.7 to 45.6 ml/min
Patient Follow-Up
Termination of renal replacement therapy 2 days after the last CytoSorb treatment, recovery of diuresis to initial quanitity 7 days after the last CytoSorb treatment
Weaning and extubation successful 6 days after CytoSorb application
11 days after the CytoSorb application, the patient could be transferred to the normal surgical ward
Over the following days the patient was clinically stable, awake, adequately alert, mentally appropriate, and with complete oral nutrition
Final surgical healing successful following installation of a terminal ileostoma
CONCLUSIONS
The treatment with CytoSorb resulted in stabilization of vital functions (improvement in the circulatory and renal function) as well as declining doses and finally complete cessation of catecholamines
CytoSorb was safe and easy to use
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM